Cure My Disease

Don't miss your cure!

 Log in / Sign up

First human test of SSGJ-626: will it be safe?

NCT ID NCT06674525

Completed Knowledge-focused Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This early-stage trial tests a single injection of the experimental drug SSGJ-626 in healthy adults aged 18 to 45. The main goal is to check for side effects and see how the drug moves through the body. Participants are randomly assigned to receive either the drug or a placebo, and neither they nor the researchers know who gets what. The results will help decide whether further studies in patients are possible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SSGJ-626
What this could lead to
If safe, this could pave the way for future studies of SSGJ-626 in specific diseases.
What could go wrong
This is an early Phase 1 trial in healthy people, so it cannot yet show whether the drug works for any condition. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS (HS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY SUBJECTS (HS)

Contacts and locations

Locations

  • Shanghai General Hospital

    Shanghai, 200080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.